(Not) Ignoring Investor Metrics in Biotech Pitch Decks
Founders, let’s address a pervasive issue in biotech: the chronic neglect of financial metrics in pitch decks. Investors aren’
Michael Lewis: The Court Jester of Capitalism’s Machine Room
Michael Lewis has made a career of peering behind the velvet curtain of capitalism and calmly announcing: “It’s mostly
Fat-Tailed Distributions and Black Swan Events: Why They Matter
The concepts of fat-tailed distributions and black swan events, as popularized by Nassim Nicholas Taleb in seminal work "The
Black Swans in Drug Discovery—Anticipating the Unpredictable
Drug discovery operates at the intersection of science, technology, and uncertainty. Despite advances in high-throughput screening, computational modeling, and clinical
Middle-aged, Male, and Mildly Annoyed: Why I Stopped Going to Startup Events
If you’ve read this blog—ramblings, thought-leadership, or the digital equivalent of shouting into the void—you might be
Guide to Critically Assessing Early-Stage Pharma and Biotech Pitch Decks
1. Pricing and Reimbursement Pressures
1.1 Early Pricing Negotiations
* The New Reality:
* Payers and HTA bodies, particularly in Europe,
IPOs: Europe’s Public Markets Problem
For biotech companies, the IPO is like a debutante ball—a grand public coming-out party where you hope to dazzle
The Private Market Data Illusion: Lies, Damn Lies, and PitchBook Statistics
Venture capital and private equity thrive on numbers—IRRs, TVPIs, MOICs—each acronym an attempt to quantify success in an
What I Learned Losing a Million Dollars (And Why Taleb Approves)
There are many books about how to make money. There are far fewer about how people actually lose it. What
Feeding on the Fine Print: What The Art of Vulture Investing Taught Me About Survival
There are very few finance books that you can read without needing a double espresso or a minor existential crisis
